{"id":78786,"date":"2026-09-04T16:31:31","date_gmt":"2026-09-04T08:31:31","guid":{"rendered":"https:\/\/flcube.com\/?p=78786"},"modified":"2026-09-04T16:31:31","modified_gmt":"2026-09-04T08:31:31","slug":"bettas-ensartinib-wins-nmpa-approval-for-third-indication-as-adjuvant-therapy-in-alk-positive-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78786","title":{"rendered":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Betta Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/300558:SHE\">SHE: 300558<\/a>)<\/strong> announced that <strong>ensartinib (trade name: Ensacove)<\/strong> has been approved by <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for a new indication: <strong>adjuvant therapy<\/strong> for patients with <strong>anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)<\/strong> at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the <strong>third indication<\/strong> for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>New indication approval<\/td><\/tr><tr><td>Product<\/td><td><strong>ensartinib (Ensacove)<\/strong><\/td><\/tr><tr><td>New Indication<\/td><td>Adjuvant therapy for <strong>ALK-positive NSCLC<\/strong> (stages IB\u2013IIIB) after surgical resection, irrespective of physician-determined adjuvant chemotherapy indication<\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Indication Count<\/td><td>Third approved indication in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-approval-history\" class=\"wp-block-heading\">Drug Profile &amp; Approval History<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>ensartinib<\/strong>, a novel, potent and highly selective <strong>next-generation ALK inhibitor<\/strong> developed by <strong>Betta Pharmaceuticals<\/strong><\/li>\n\n\n\n<li><strong>Approval History in China:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>2020<\/strong> \u2013 Second-line treatment of ALK-positive NSCLC<\/li>\n\n\n\n<li><strong>2022<\/strong> \u2013 First-line treatment of ALK-positive NSCLC<\/li>\n\n\n\n<li><strong>2026<\/strong> \u2013 Adjuvant therapy for resected ALK-positive NSCLC (stages IB\u2013IIIB)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> The adjuvant approval completes ensartinib\u2019s coverage across the treatment continuum \u2014 from advanced disease lines into the curative-intent setting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-adjuvant-therapy-study\" class=\"wp-block-heading\">Clinical Evidence \u2013 Adjuvant Therapy Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Interpretation<\/th><\/tr><\/thead><tbody><tr><td>2-year disease-free survival (DFS) rate<\/td><td><strong>86.4%<\/strong><\/td><td>High sustained DFS at 2 years<\/td><\/tr><tr><td>Hazard ratio (HR)<\/td><td><strong>0.20<\/strong><\/td><td>Represents an <strong>80% reduction in the risk of recurrence<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The clinical study underpinning the approval demonstrated that <strong>ensartinib<\/strong> adjuvant therapy achieved a <strong>2-year DFS rate of 86.4%<\/strong> with a hazard ratio of <strong>0.20<\/strong> \u2014 translating into an <strong>80% reduction in the risk of recurrence<\/strong> for resected ALK-positive NSCLC patients. The broad label, covering patients both with and without a physician-determined indication for adjuvant chemotherapy, maximizes the eligible population.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early-stage expansion:<\/strong> Moving into adjuvant therapy opens a substantially larger and earlier patient population for <strong>ensartinib<\/strong>, where treatment duration and commercial value typically exceed late-line settings<\/li>\n\n\n\n<li><strong>Broad label advantage:<\/strong> Inclusion of chemotherapy-indicated and chemotherapy-non-indicated patients gives clinicians flexibility and widens commercial reach versus more restrictive adjuvant labels<\/li>\n\n\n\n<li><strong>Competitive landscape:<\/strong> The 80% recurrence risk reduction positions <strong>ensartinib<\/strong> strongly against other ALK inhibitors seeking to establish adjuvant credentials in China<\/li>\n\n\n\n<li><strong>Lifecycle value:<\/strong> A third indication reinforces <strong>Betta Pharmaceuticals\u2019<\/strong> (SHE: 300558) flagship oncology asset and extends its relevance as the ALK-positive NSCLC market shifts earlier in the disease course<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug commercialization, indication adoption and market potential are forward-looking and subject to risks and uncertainties, including competitive developments, reimbursement outcomes and clinical practice patterns. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u672f\u540e\u8f85\u52a9\u6cbb\u7597\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u672f\u540e\u8f85\u52a9\u6cbb\u7597\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-114066e7-87d2-4db1-8a0a-789b0d08f137\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u672f\u540e\u8f85\u52a9\u6cbb\u7597\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\">\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u672f\u540e\u8f85\u52a9\u6cbb\u7597\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u76d0\u9178\u6069\u6c99\u66ff\u5c3c\u80f6\u56ca\u672f\u540e\u8f85\u52a9\u6cbb\u7597\u9002\u5e94\u75c7\u83b7\u5f97\u836f\u54c1\u6ce8\u518c\u8bc1\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-114066e7-87d2-4db1-8a0a-789b0d08f137\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[231,15,1030],"class_list":["post-78786","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-betta-pharmaceuticals","tag-product-approvals","tag-she-300558"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78786\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC\" \/>\n<meta property=\"og:description\" content=\"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78786\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:31:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC\",\"datePublished\":\"2026-09-04T08:31:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Betta Pharmaceuticals\",\"Product approvals\",\"SHE: 300558\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78786#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78786\",\"name\":\"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:31:31+00:00\",\"description\":\"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78786\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78786#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78786","og_locale":"en_US","og_type":"article","og_title":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC","og_description":"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.","og_url":"https:\/\/flcube.com\/?p=78786","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:31:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78786#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78786"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC","datePublished":"2026-09-04T08:31:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78786"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Betta Pharmaceuticals","Product approvals","SHE: 300558"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78786#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78786","url":"https:\/\/flcube.com\/?p=78786","name":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:31:31+00:00","description":"Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China\u2019s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78786#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78786"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78786#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Betta\u2019s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78786"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78786\/revisions"}],"predecessor-version":[{"id":78794,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78786\/revisions\/78794"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}